Author

Muriel Newinger-Porte

Observed names: M. Newinger-Porte, Muriel Newinger, Muriel Newinger-porte

Institution: Groupe Hospitalier de la Région de Mulhouse et Sud Alsace

Observed institutions: Centre Hospitalier de Mulhouse, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace

OpenAlex ID: A5064029162

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

2024 · Xavier Leleu, Cyrille Hulin, et al. · Nature Medicine · 129

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022–05)

2025 · Arthur Bobin, Anais Schavgoulidze, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort

2024 · T. Chalopin, M. Macro, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

2026 · Arthur Bobin, Lisa Durocher, et al. · Blood Cancer Journal

Central nervous system involvement in multiple myeloma as a first manifestation of relapse and potential diagnostic pitfall

2026 · Jessy Ranaivomanana, Léa Ryffel, et al. · Cytometry Part B Clinical Cytometry

Works count: 5

Citation count: 133

H-index: 2

I10-index: 1